An Adaptive Phase 2, Open-Label, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix Trifluoroacetate, a Gonadotropin-releasing Hormone (GnRH) A... - Trial 2020-000543-31
Access comprehensive clinical trial information for 2020-000543-31 through Pure Global AI's free database. This phase not specified trial is sponsored by Antev Ltd. and is currently status unknown. The study focuses on Prostate cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2020-000543-31
Trial Details
EU Clinical Trials Register • 2020-000543-31
An Adaptive Phase 2, Open-Label, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix Trifluoroacetate, a Gonadotropin-releasing Hormone (GnRH) A...
Study Focus
Sponsor & Location
Antev Ltd.
Timeline & Enrollment
N/A
N/A
N/A
ICD-10 Classifications
Malignant neoplasm of prostate
Hyperplasia of prostate
Disorder of prostate, unspecified
Other disorders of prostate
Carcinoma in situ: Prostate
Data Source
EU Clinical Trials Register
2020-000543-31
Non-Device Trial